Restless legs syndrome - New insights into clinical characteristics, pathophysiology, and treatment options

Journal of Neurology, Supplement

Volumn 251, Issue 6, 2004, Pages

  Stiasny Kolster, Karin ^a   Trenkwalder, C ^a   Fogel, W ^a   Greulich, W ^a   Hahne, M ^a   Lachenmayer, L ^a   Oechsner, M ^a   Oertel, W H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Pathophysiology; PLMS; RLS; Therapy dopamine agonist

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LEVODOPA; LISURIDE; OPIATE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

CHROMOSOME 12Q; CHROMOSOME 14Q; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE LOCUS; HUMAN; HYPERALGESIA; IRON METABOLISM; NOCICEPTION; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME;

CENTRAL NERVOUS SYSTEM; DOPAMINE; DOPAMINE AGONISTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERALGESIA; IRON METABOLISM DISORDERS; RESTLESS LEGS SYNDROME; SLEEP DISORDERS;

EID: 5644259703     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-1609-3     Document Type: Conference Paper

References (29)

1. Allen R, Picchietti D, Hening W, Trenkwalder C, Walters AS, Montplaisir J and the participants in the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institue of Health in collaboration with members of the International Restless Legs Syndrome Study Group (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Medicine 4:101-119
2. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ (2001) MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56:263-265
3. Benes H, Heinrich CR, Ueberall MA, Kohnen R (2004) Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 27:674-682
4. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C (2004) Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 164:196-202
5. Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G (2003) Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 126:1485-1492
6. Connor JR, Wang XS, Patton SM, Menzies SL, Troncoso JC, Earley CJ, Allen RP (2004) Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 62:1563-1567
7. Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau GA (2001) Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 69:1266-1270
8. Earley CJ, Connors JR, Allen RP (1999) RLS patients have abnormal reduced CSF ferritin compared to normal controls. Neurology 52:A111-A112
9. Earley CJ, Heckler D, Allen RP (2004) The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 5:231-235
10. Happe S, Zeitlhofer J (2003) Abnormal cutaneous thermal thresholds in patients with restless legs syndrome. J Neurol 250:362-365
11. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L (2004) Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5:237-246
12. Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C (2003) Severity rating of Restless Legs Syndrome: Review of ten years experience with the RLS-6 scales in clinical trials. Sleep 26:A342
13. Levchenko A, Montplaisir J, Dube M-P, Riviere J-B, St-Onge J, Turecki G, Xiong L, Thibodeau P, Desautels A, Verlaan DJ, Rouleau GA (2004) The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol 55:887-891
14. Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J (2004) Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 55:372-380
15. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B (1999) Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52:938-943
16. Oertel WH, Benes H, Happe S, Kohnen R, Leroux M, Stiasny-Kolster K (2004) Efficacy of cabergoline for the treatment of sensori-motor symptoms and sleep disturbances in restless legs syndrome: a placebo-controlled, 5-week, double-blind, randomized, multicenter, polysomnographic study. Mov Disord 19:S425
17. Pittock SJ, Parret T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE (2004) Neuropathology of primary restless legs syndrome: Absence of specific tau- and alpha-synuclein pathology. Mov Disord 19:695-699
18. Stiasny K, Oertel WH, Trenkwalder C (2002) Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev 6:253-265
19. Stiasny-Kolster K, Benes H, Peglau I, Hornyak M, Holinka B, Wessel K, Emser W, Leroux M, Kohnen R, Oertel WH (2004) Effective cabergoline treatment in idiopathic restless legs syndrome (RLS): a randomized, double-blind, placebo-controlled, multicenter dose-finding study followed by an open long-term extension. Neurology (in press)
20. Stiasny-Kolster K, Kohnen R, Schollmayer E, Möller JC, Oertel WH, the Rotigotine SP 666 Study Group (2004) Patch-application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome - a double-blind placebo controlled pilot study. Mov Disord DOI: 10.1002/mds.20251
21. Stiasny-Kolster K, Magerl W, Oertel WH, Möller JC, Treede R-D (2004) Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 127:1-10
22. Stiasny-Kolster K, Möller C, Zschocke J, Bandmann O, Cassel W, Oertel WH, Hoffmann G (2004) Normal dopaminergic and serotonergic metabolites in CSF and blood of restless legs syndrome patients. Mov Disord 19:192-196
23. The International Restless Legs Syndrome Study Group (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs. Sleep Medicine 4:121-132
24. Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P, Saletu-Zyhlarz G, Telstad W, Ferini-Strambi L (2004) Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75:92-97
25. Trenkwalder C, Hundemer HP, Lledo A, et al., and on behalf of the PEARLS Study Group (2004) A randomized long-term placebo-controlled multicenter trial of pergolide in the treatment of restless legs syndrome with central evaluation of polysomnographic data. Neurology 62:1391-1397
26. Trenkwalder C, Paulus W (2004) Why do restless legs occur at rest? - pathophysiology of central and peripheral structures in RLS. Neurophysiology of RLS (part 2). Clin Neurophysiol 115:1975-1988
27. Trible GG, Waldhauser F, Sycha T, Auff E, Zeitlhofer J (2003) Urinary 6-hydroxy-melatonin-sulfate excretion and circadian rhythm in patients with restless legs syndrome. J Pineal Res 35:295-296
28. Walters AS (1995) Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 10:634-642
29. Winkelmann J, Müller-Myhsok B, Wittchen H-U, Hock B, Prager M, Pfister H, Strohle A, Eisensehr I, Dichgans M, Gasser T, Trenkwalder C (2002) Complex segregation analysis of restless legs syndrome provides evidence for an autosomal-dominant mode of inheritance in early age at onset families. Ann Neurol 52:279-302